Regenerative cell therapy biotech uses IPO to blast into human trials

[cafead]

via FibroBiologics’ vision: The company is setting out to develop and commercialize fibroblast cell-based therapies for multiple diseases, such as degenerative disc disease, multiple sclerosis, wound healing and cancer. To make the leap into human trials, the biotech stepped away from traditional fundraising by going for its own initial public offering earlier this year.

article source